Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes
CD38 is a transmembrane glycoprotein that functions both as a receptor and an ectoenzyme, playing key roles in the regulation of calcium signaling and migration of immune cells to tumor microenvironments. High expression on multiple myeloma (MM) cells and limited expression on normal cells makes CD38 an ideal target for the treatment of MM patients. Two monoclonal antibodies directed at CD38, isatuximab and daratumumab, are available for use in patients with relapsed and/or refractory MM (RRMM); daratumumab is also approved in newly diagnosed MM and light-chain amyloidosis. Clinical experience has shown that anti-CD38 antibody therapy is transforming treatment of MM owing to its anti-myeloma efficacy and manageable safety profile. Isatuximab and daratumumab possess similarities and differences in their mechanisms of action, likely imparted by their binding to distinct, non-overlapping epitopes on the CD38 molecule. In this review, we present the mechanistic properties of these two antibodies and outline available evidence on their abilities to induce adaptive immune responses and modulate the bone marrow niche in MM. Further, we discuss differences in regulatory labeling between these two agents and analyze recent key clinical trial results, including evidence in patients with underlying renal impairment and other poor prognostic factors. Finally, we describe the limited existing evidence for the use of isatuximab or daratumumab after disease progression on prior anti-CD38 mono- or combination therapy, highlighting the need for additional clinical evaluations to define optimal anti-CD38 antibody therapy selection and sequencing in RRMM.
European Commission approves Sarclisa® (isatuximab) for adults with relapsed and refractory multiple myeloma. Press release. Sanofi; June 2, 2020. Accessed March 16, 2022. https://www.sanofi.com/en/media-room/press-releases/2020/2020-06-02-12-47-38
Darzalex. Prescribing information. Janssen; March 2022. Accessed March 16, 2022. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf
Darzalex Faspro. Prescribing information. Janssen; January 2022. Accessed March 16, 2022. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf
Sarclisa. Prescribing information. Sanofi; March 2021. Accessed March 16, 2022. https://products.sanofi.us/Sarclisa/sarclisa.pdf
European Medicines Agency. Sarclisa, INN-Ixatuximab. Summary of product characteristics. 2021. Accessed March 16, 2022. https://www.ema.europa.eu/en/documents/product-information/sarclisa-epar-product-information_en.pdf
European Commission grants marketing authorisation for Darzalex (daratumumab) subcutaneous formulation for all currently approved daratumumab intravenous formulation indications. Press release. Janssen; June 4, 2020. Accessed March 16, 2022. https://myelomabeacon.org/pr/2020/06/04/european-approval-subcutaneous-darzalex/
Darzalex. European Medicines Agency. Updated August, 2020. Accessed March 16, 2022. https://www.ema.europa.eu/en/documents/overview/darzalex-epar-medicine-overview_en.pdf
Wetzel M, Nicolazzi C, Cai T, Vallee F, Deckert J, Dumontet C et al (2013) Preclinical characterization of SAR650984, a humanized anti-CD38 antibody for the treatment of multiple myeloma. International Myeloma Workshops: Kyoto, Japan. P288.
Lammerts van Bueren J, Jakobs D, Kaldenhoven N, Roza M, Hiddingh S, Meesters J, et al. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. Blood. 2014;124:3474. doi: 10.1182/blood.V124.21.3474.3474.
DOI
Neri P, Maity R, Tagoug I, McCulloch S, Duggan P, Jimenez-Zepeda V, et al. Immunome single cell profiling reveals T cell exhaustion with upregulation of checkpoint inhibitors LAG3 and Tigit on marrow infiltrating T lymphocytes in daratumumab and IMiDs resistant patients. Blood. 2018;132(Suppl. 1):242. doi: 10.1182/blood-2018-99-117531.
DOI
Moreau P, Parmar G, Prince M, Ocio E, Karanes C, Madan S et al 2021 A multi-center, Phase 1b study to assess the safety, pharmacokinetics and efficacy of subcutaneous isatuximab plus pomalidomide and dexamethasone, in patients with relapsed/refractory multiple myeloma. International Myeloma Workshop - XVIII. Abstract P-207
Study of carfilzomib, daratumumab and dexamethasone for patients with relapsed and/or refractory multiple myeloma (CANDOR). ClinicalTrials.gov identifier: NCT03158688. Accessed March 16, 2022. https://clinicaltrials.gov/ct2/show/NCT03158688
Multinational clinical study comparing isatuximab, carfilzomib and dexamethasone to carfilzomib and dexamethasone in relapse and/or refractory multiple myeloma patients (IKEMA). ClinicalTrials.gov identifier: NCT03275285. Accessed March 16, 2022. https://clinicaltrials.gov/ct2/show/NCT03275285
Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T et al 2020 Isatuximab plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (IKEMA): interim analysis of a phase 3, randomized, open-label study. European Hematology Association; June 14, 2020. Abstract LB2603
APOLLO (MMY3013) Study. JanssenMD Professional Information Resource. December 18, 2020. Accessed August 31, 2021. https://www.janssenmd.com/darzalex-faspro/clinical-data/clinical-studies/apollo-mmy3013-study
Beksac M, Richardson P, Unal A, Corradini P, DeLimpasi S, Gulbas Z et al 2020 Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma and soft-tissue plasmacytomas: ICARIA-MM subgroup analysis. American Society of Hematology Annual Meeting 2020. Abstract 2289
Richardson P, Harrison S, Facon T, Yong K, Raje N, Alegre A et al 2020 Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with 1q21 gain: insights from phase 1 and phase 3 studies. Presented at 25th Annual Congress of European Hematology Association; June 11–14, 2020; Virtual. Accessed March 16, 2022. https://library.ehaweb.org/eha/2020/eha25th/293508
Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, et al. Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM). ESMO Virtual Plenary: VP5-2022. Ann Oncol. 2022;33:664–665. doi: 10.1016/j.annonc.2022.04.013.
DOI
Richardson P, Perrot A, San-Miguel J, Beksac M, Spicka I, Leleu X, et al. Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM) J Clin Oncol. 2021;39(Suppl. 15):8017–8017. doi: 10.1200/JCO.2021.39.15_suppl.8017.
DOI
Becnel M, Horowitz S, Thomas S, Iyer S, Patel K, Manasanch E, et al. Descriptive analysis of isatuximab use following prior daratumumab in patients with relapsed/refractory multiple myeloma. Blood. 2020;136(Suppl. 1):20–21. doi: 10.1182/blood-2020-140526.
DOI
Goldschmidt H, Mai E, Nievergall E, Fenk R, Bertsch U, Tichy D, et al. Addition of isatuximab to lenalidomide, bortezomib and dexamethasone as induction therapy for newly-diagnosed, transplant-eligible multiple myeloma patients: the phase III GMMG-HD7 trial. Blood. 2021;138(Suppl. 1):463. doi: 10.1182/blood-2021-145097.
DOI
